Disease
Treatment -standard versus attenuated NHLi: Chronic lymphoid leukaemia Standard: Rituximab-bendamustin or chlorambucil standard dose Attenuated: Chlorambucil reduced dose or BSC NHLI: Diffuse large B-cell lymphoma Standard: R-CHOP or R-COMP or rituximab-bendamustin( 90mg/m2 d1,2) Attenuated: Rituximab-bendamustin (≤70mg/m2 d1,2) or R-COMP (≤75% dose) or rituximab monotherapy NHLi: Lymphoplasmacytic NHL (Waldenström macroglobulinemia)
Standard: Rituximab-bendamustin or chlorambucil standard dose Attenuated: Chlorambucil reduced dose or BSC NHLi: Small lymphocytic lymphoma One patient received an attenuated treatment with Leukeran.
NHLi: MALT-Lymphoma One patient with an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), was classified as unfavourable based on an advanced Ann Arbor stage 4 and received a standard therapy including rituximab and cladribine within a clinical study. Another patient had Ann Arbor stage 1 and were classified as favourable. One patient received standard therapy with R-COMP NHLi: Hairy cell leukaemia
One patient with hairy cell leukaemia was classified as favourable and received a standard therapy using cladribine.
NHLa: Mantle cell non-Hodgkin lymphoma Two cases of mantle cell NHL were classified as unfavourable based on an Ann Arbor stage 4. One patient received standard dose rituximab-Bendamustin (90mg/m2, d1,2), One patient was treated by reduced dose (60mg/m2, d1,2).
NHLa: B-cell prolymphocytic leukaemia One patient with B-cell prolymphocytic leukaemia was classified as unfavourable and received an attenuated therapy with rituximab-bendamustin (60mg/m2, d1,2).
NHLa: T-cell non-Hodgkin lymphoma Based on the biology of the disease two cases of T-cell non-Hodgkin lymphoma (anaplastic large cell T-NHL, peripheral T-NHL, not otherwise specified, intestinal T-NHL, secondary T-NHL from Mycosis fungoides) were classified as unfavourable. One patient received a standard therapy with COMP, whereas the other one received an attenuated therapy with alemtuzumab-COMP (75% Principal component analyses (PCA, see Figure 1 ) -association between parameters and PCA axes Supplementary Table1 shows which parameters are strongest summarized by the individual principal components. The first two components gain significance in a bootstrapped broken stick test and are depicted as PCA Axes 1 and 2 in Figure  1 . The explanatory power of the total variance of patient for the axes is 17% for PCA Axis 1, 10% for Axis 2, 9% for Axis 3, and 7 % for Axis 4. The higher a parameter scores on an axis, in absolute values, the stronger the parameter is reflected by the axis, with a potential range of the scores from 1 to -1. Please note that positive versus negative scores along one axis reflect opposing trends (e.g. serum albumin versus WHO score on PCA Axis 1). In the table below, any parameter scoring over 40% (i.e. cut-off >0.4 or <-0.4, respectively) is highlighted. Those parameters scoring over 0.4 (positively loading on axes) are marked in red, and those scoring less than -0.4 (negatively loading on axes) in blue, with the parameters associated with PCA1 additionally marked in bold, and PCA2 additionally marked in bold blue.
Parameters not strongly associated with any axes ("undefined") are in grey. 
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